Register for our free email digests:
Latest From CV Therapeutics Inc.
Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.
Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.
Two cardiac stress test agents marketed in the US by Astellas Pharma are the subject of a new warning from the FDA over a "rare but serious risk of heart attack and death" in certain patients, prompted by recent reports of serious adverse events.
A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Vibrynt Inc.
- Senior Management
Beverly Huss, Pres. & CEO
Brett Hale, CFO
Ted Bender, VP, R&D
- Contact Info
Phone: (650) 362-6100
701 Galveston Dr.
Redwood City, CA 94063-4700
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.